Yuk Ting Ma

Medicine & Life Sciences

1. Hepatocellular Carcinoma 100%
2. Sorafenib 81%
3. gemcitabine 42%
4. Survival 35%
5. Capecitabine 33%
6. Pancreatic Neoplasms 25%
7. Biliary Tract Neoplasms 25%
8. Neoplasms 22%
9. Germ Cell and Embryonal Neoplasms 19%
10. Adenocarcinoma 17%
11. Cancer Vaccines 16%
12. Therapeutics 15%
13. Progression-Free Survival 14%
14. Drug Therapy 14%
15. N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 13%
16. Testicular Germ Cell Tumor 11%
17. 130-nm albumin-bound paclitaxel 11%
18. Safety 11%
19. Randomized Controlled Trials 10%
20. nintedanib 10%
21. Neutrophils 10%
22. Systematic Reviews 9%
23. CCAAT-Enhancer-Binding Protein-alpha 9%
24. Phase II Clinical Trials 9%
25. Clinical Trials, Phase I 9%
26. Standard of Care 9%
27. Lymphocytes 9%
28. Leucovorin 8%
29. Ependymoma 8%
30. Liver Diseases 8%
31. Haploidy 8%
32. Oxaliplatin 8%
33. Textbooks 7%
34. Fluorouracil 7%
35. Pancreaticoduodenectomy 7%
36. Epigenomics 7%
37. Bilirubin 7%
38. Prothrombin 7%
39. Gastric Acid 7%
40. Vitamin K 7%
41. Macrophage Activation 7%
42. Chemoradiotherapy 7%
43. Observation 7%
44. Lymphocyte Activation 7%
45. Granulocyte-Macrophage Colony-Stimulating Factor 6%
46. Chronic Hepatitis C 6%
47. Clinical Trials 6%
48. Albumins 6%
49. Myeloid Cells 6%
50. Liver Transplantation 6%